NCT04599972 - An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2) | Biotech Hunter

Enrollment

304

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

January 21, 2022

Study Completion Date

January 28, 2022

Conditions

Presbyopia

Interventions

DRUG

CSF-1

One drop bilaterally twice daily for approximately 2 weeks.

DRUG

Vehicle

One drop bilaterally twice daily for approximately 2 weeks.

Trial Locations (18)

14618

Orasis Investigative Site, Rochester

18704

Orasis Investigative Site, Kingston

24502

Orasis Investigative Site, Lynchburg

33484

Orasis Investigative Site, Delray Beach

61201

Orasis Investigative Site, Rock Island

78229

Orasis Investigative Site, San Antonio

78613

Orasis Investigative Site, Cedar Park

80120

Orasis Investigative Site, Littleton

84015

Orasis Investigative Site, Clinton

84020

Orasis Investigative Site, Draper

85032

Orasis Investigative Site, Phoenix

85202

Orasis Investigative Site, Mesa

85225

Orasis Investigative Site, Chandler

91345

Orasis Investigative Site, Mission Hills

92663

Orasis Investigative Site, Newport Beach

92843

Orasis Investigative Site, Garden Grove

94954

Orasis Investigative Site, Petaluma

06810

Orasis Investigative Site, Danbury